Medidata Drives Diversity in Clinical Trials, Passing 30,000 Studies and 9 Million Participants
Known for its ground-breaking technological innovations in clinical trials, Medidata, a Dassault Systèmes company, has exceeded 30,000 clinical trials and 9 million study participants. These milestones, achieved together with more than 2,100 global customers and partners, have been fueled by Medidata’s platform and life sciences solutions that power smarter treatments and healthier people, while driving greater access to trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005168/en/
“As a patient advocate and study participant, I understand the significance of these milestones,” said Anne Marie Mercurio, research advocate and Medidata Patient Insights Board Chair. “And beyond the numbers and the data, Medidata’s ongoing commitment to infusing the patient voice into trial designs and solutions, is helping to create a better and more inclusive experience for all participants in clinical studies.”
Medidata has the deepest, widest platform of pioneering programs including decentralized clinical trials, increasing diversity in clinical studies, and advanced AI solutions for trial design and simulation, site selection, and Synthetic Control Arms. And Medidata technologies and services are driving more value for customers, helping reach critical development milestones faster, including saving an average of one month in study build time and two months in conducting studies.
Rose Kidd, president, Operations Delivery at ICON, commented: “At ICON, technology is core to how we deliver customer needs effectively and efficiently, through our own proprietary technologies to working with leaders in their field like Medidata. ICON has a long history with Medidata as its first CRO partner. We are proud to collaborate together to create industry-leading solutions that drive best-in-class performance in clinical development.”
Maribel Hernandez, vice president, Clinical Operations & Special Projects at PTC Therapeutics stated: “Clinical trials in rare disease are complex and unpredictable. Since becoming a Medidata customer in 2016, we have benefited from their experience and innovative spirit, and gained efficiencies to bring novel medicines to patients in need.”
Mike McDevitt, senior vice president, Biometrics at Syneos Health, said: “We have collaborated with Medidata for over 16 years and during this time the company’s dedication to service delivery and clinical trials innovation has further enabled Syneos Health to serve our customers and accelerate the development of drugs and devices. Medidata has made groundbreaking contributions to technology and clinical research – contributions that stand out in our industry – and we are pleased to join them in celebrating these significant operational milestones.”
“This 30,000 trial milestone is a remarkable achievement and a testament to the hard work of so many at Medidata who support trials, develop innovations in AI, and serve our customers while putting patients first,” said Pascal Daloz, Medidata CEO. “We thank the 9 million trial participants who chose clinical trials as part of their healthcare journey and the customers who partnered with us to advance human health…and we’re just getting started!”
Leveraging this volume of trials, patients and data, Medidata delivers unmatched results in the industry. With studies conducted in more than 140 countries, Medidata is involved in nearly 40% of company-initiated trial starts globally. Approximately 70% of novel drugs approved by the U.S. Food and Drug Administration (FDA) in 2022 were developed with Medidata software. And in the critical area of rare disease research, Medidata has supported more than 2,000 studies representing more than 320,000 participants.
See our Medidata fact sheet, and review our Awards and Recognition to learn more.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,100+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005168/en/
Contact information
Tom Paolella
Senior Director, Corporate Communications & Affairs
+1-848-203-7596
thomas.paolella@3ds.com
Paul Oestreicher
External Communications Director
+1-917-522-4692
paul.oestreicher@3ds.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alveo Technologies Announces ISO 13485:2016 Certification21.3.2023 14:45:00 CET | Press release
Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, today announced its quality management system (QMS) has achieved ISO 13485:2016 certification for the design, development and manufacture of in vitro diagnostic kits and analyzers for the detection of infectious disease. The globally recognized ISO 13485 standard, published by the International Standards Organization, sets out requirements for establishing and maintaining quality management systems for the medical device industry. Compliance with the ISO 13485 standard is required for companies to market medical devices in many markets, including the European Union, Canada, Japan, and Australia. In addition, the U.S. Food and Drug Administration has announced plans to harmonize its existing medical device QMS requirements with ISO 13485, proposing new regulations that incorporate ISO 13485 as the foundational requirements. “We are thrilled to achieve ISO 13
Wemade Presents ‘ Wateree’s Enhancement Support Event’ to Boost Growth in MIR M21.3.2023 14:00:00 CET | Press release
Wemade's blockbuster MMORPG MIR M: Vanguard and Vagabond (hereinafter "MIR M") is holding the "Wateree’s Enhancement Support" event starting from March 21st, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005487/en/ ‘Wateree’s Enhancement Support Event’ for MIR M starts on March 21, 2023 (Graphic: Wemade) For two weeks, users can participate in two attendance events called "Wateree's Enhancement Support 7 Days Check-in," and "Wateree's Illusory Mystic Realm Support 7 Days Check-in." Simply by checking in, users can obtain abundant rewards such as "Enhancement Stone," "Reforging Stone," "Oil of Blessing," "Illusory Mystic Realm Entry Ticket," and the EXP buff item, "Growth Draught," and more, depending on the number of attendances in the Check-in events. There are also special items available in the in-game Shop for improving crafting and enhancement mastery. The "Wateree's Crafting Mastery Support" package, which
MIR4 Updates ‘Sabuk Clash’ to Determine the Most Powerful Clan21.3.2023 14:00:00 CET | Press release
Wemade’s blockbuster MMORPG MIR4 updated Sabuk Clash, clan vs. clan Castle Siege, on March 21st. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005465/en/ MIR4 Updates ‘Sabuk Clash,’ a tournament style Castle Siege content to determine the Emperor’s Clan, on March 21 (Graphic: Wemade) “Sabuk Clash” is a tournament style Castle Siege content where King’s clans from all servers in each region gather in the Domination Server and fight to become the Emperor’s clan. Only Bicheon Castle King’s clans can participate. The winning clan then becomes the Emperor’s clan, which can collect taxes from the Kings of all servers in each region, adjust individual tax rates per server, and is given authority to manage the Sabuk Castle territory. The first round begins on March 26th at 10 pm, and a new round will be held every week for a total of 3 rounds over 3 weeks. In the first round, a total of 16 clans fight to capture one of the 8
Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm21.3.2023 13:02:00 CET | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA). Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005445/en/ Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA. (Photo: Business Wire) “There is an estimated 1.1 million Americans living with an AAA1. Majority of these patients are asymptomatic and many are unaware of their disease until a rupture occurs. This is a catastrophic medical emergency, resulting in over 10,000 deaths each year,” said Philip Batista, MD, Associate Program Director, Vascular and Endovascular Surgery Residency, Cooper. “This algorithm is a powerful ne
José Baselga Research Fund Announces First-Ever Grant to Advance Prion Disease Research21.3.2023 13:02:00 CET | Press release
The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders. JBRF was created by the Baselga family in memory of Dr. José Baselga, a physician-scientist who dedicated his life to the advancement of cancer therapy before passing away two years ago today from Creutzfeldt-Jakob Disease (CJD), an extremely rare, fatal neurodegenerative condition. The Baselga Grant will honor Jose’s legacy and support scientists in the pursuit of understanding, and eradicating, prion diseases such as CJD. “Our family feels incredibly lucky to have had such an amazing father and husband for as long as we did, and we are committed to continuing his legacy of improving people’s lives through innovative medicines,” commented Clara Baselga-Garriga, daughter of José and studen